M
Mary J. Fidler
Researcher at Rush University Medical Center
Publications - 116
Citations - 7395
Mary J. Fidler is an academic researcher from Rush University Medical Center. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 21, co-authored 95 publications receiving 5610 citations. Previous affiliations of Mary J. Fidler include Trinity School of Medicine.
Papers
More filters
Journal ArticleDOI
Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
TL;DR: Efforts are underway to identify clinical and molecular predictors in patients who may benefit from treatment with EGFR TKIs, which may be used in Patients who have failed treatment with first-generation EGFRTKIs.
Journal ArticleDOI
P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy
Roy S. Herbst,Paul Baas,Jose Luis Perez-Gracia,Enriqueta Felip,Dong Wan Kim,Ji-Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Veerle Surmont,Gilberto de Castro,Marcelo Garrido,Yue Shentu,Marisa Dolled-Filhart,Ellie Im,Edward B. Garon +18 more
TL;DR: The aim of this research was to improve the quality and quantity of clinical trials in Cuba and to contribute towards the humanizing of immunology in the country.
Journal Article
Treatment of locally advanced non-small cell lung cancer.
TL;DR: Evidence-based strategies in the treatment of locally advanced NSCLC are reviewed and new efforts for improving the poor prognosis of this disease by incorporating novel chemotherapy and biologic based regimens are presented.
Journal ArticleDOI
Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial.
Melissa Yan,Greg Andrew Durm,Hirva Mamdani,Vinicius Ernani,Salma K. Jabbour,Jarushka Naidoo,Borys Hrinczenko,Ticiana Leal,Lawrence Eric Feldman,Goetz H. Kloecker,Naomi Fujioka,Mary J. Fidler,Nasser H. Hanna +12 more
TL;DR: This data indicates that the combination of nivolumab/ipilimumab with PD-1/PD-L1 inhibition after chemoradiation (CRT) for unresectable stage III NSCLC improves overall survival.
Journal ArticleDOI
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
Christine Bestvina,Jennifer G. Whisenant,Valter Torri,Alessio Cortellini,Heather A. Wakelee,Solange Peters,Elisa Roca,Alessandro De Toma,Fred R. Hirsch,Hirva Mamdani,Balazs Halmos,Oscar Arrieta,Anne-cecile Metivier,Mary J. Fidler,Jacobo Rogado,Carolyn J Presley,Céline Mascaux,Carlo Genova,Juan Bautista Blaquier,Alfredo Addeo,Giovanna Finocchiaro,Hina Khan,Julien Mazieres,Floriana Morgillo,Jair Bar,Avinash Aujayeb,Giannis Mountzios,Vieri Scotti,Federica Grosso,Erica J. Geraedts,A. Zhumagaliyeva,Leora Horn,Marina Chiara Garassino,Javier Baena +33 more
TL;DR: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID19 surges as discussed by the authors .